Continuous Targeted Kinase Inhibitors Treatment Induces Upregulation of PD-L1 in Resistant NSCLC

Scientific Reports - United Kingdom
doi 10.1038/s41598-018-38068-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

PD-L1-Hemmer Bei Vorbehandelten Patienten Mit NSCLC

Im Focus Onkologie
2017English

NSCLC: Zwei Positive Studien Zu PD-L1-Hemmer

Im Focus Onkologie
2015English

MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status

Pneumologie
MedicinePulmonaryRespiratory Medicine
2017English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy